Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2010. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by eight individuals on April 13, 2010, at a price of £12.81 per share through the Company's Share Reward Plan. Each individual acquired 9 shares via a personal contribution (partnership element) and 9 shares via a company contribution (matching element). No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: April 13, 2010.
- Share Price: £12.81 per Ordinary share.
- Participants: Mr A P Witty, Mr J S Heslop, Mr S M Bicknell, Mr E J Gray, Mr S A Hussain, Mr D Learmouth, Mr D S Redfern, and Ms C Thomas.
- Volume per Participant: 18 shares total (9 personal, 9 company match).
- Reporting Date: April 14, 2010.